Researchers investigate the need for prioritizing COVID-19 booster vaccination.
Feng Zhang suggests Editas didn’t move quickly enough to find product targets
When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas Medicine seemed like the pacesetter. It locked up some of
March 21, 2024